Development of the antibody response in acute HIV-1 infection

AIDS

Volumn 18, Issue 3, 2004, Pages 371-381

  Aasa Chapman, Marlén M I ^a   Hayman, Anna ^a   Newton, Philippa ^a   Cornforth, David ^a   Williams, Ian ^a   Borrow, Persephone ^b   Balfe, Peter ^a,c   McKnight, Áine ^a,d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b EDWARD JENNER INST FOR VACC RES   (United Kingdom)

^c AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^d Wohl Virion Centre   (United Kingdom)

Author keywords

Antibodies; Autologous; Heterologous; HIV 1; Neutralization; Seroconversion

Indexed keywords

ANTIRETROVIRUS AGENT; AUTOANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CASE REPORT; CELL LINE; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; VIREMIA; VIRUS ENVELOPE; VIRUS RECOMBINANT;

ACUTE DISEASE; ADULT; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MALE; PHYLOGENY; VIRAL LOAD; VIREMIA;

EID: 1642373711     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200402200-00002     Document Type: Article

References (47)

1. Stekler J, Collier A. Treatment of primary HIV. Curr Infect Dis Rep 2002, 4:81-87.
2. Katzenstein TL, Pedersen C, Nielsen C, Lundgren JD, Jakobsen PH, Gerstoft J. Longitudinal serum HIV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcome. AIDS 1996, 10:167-173.
3. Mellors JW, Rinaldo CR, Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
4. Bruisten SM, Frissen PH, van Swieten P, Harrigan PR, Kinghorn I, Larder B, et al. Prospective longitudinal analysis of viral load and surrogate markers in relation to clinical progression in HIV type 1-infected persons. AIDS Res Hum Retroviruses 1997, 13: 327-335.
5. Lyles RH, Munoz A, Yamashita TE, Bazmi H, Detels R, Rinaldo CR, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis 2000, 181:872-880.
6. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod C, Borkowsky W, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994, 68:4650-4655.
7. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994, 68:6103-6110.
8. Ariyoshi K, Harwood E, Chiengsong-Popov R, Weber J. Is clearance of HIV-1 viraemia at seroconversion mediated by neutralising antibodies? Lancet 1992, 340:1257-1258.
9. Pellegrin I, Legrand E, Neau D, Bonot P, Masquelier B, Pellegrin JL, et al. Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 11:438-447.
10. Pilgrim AK, Pantaleo C, Cohen OJ, Fink LM, Zhou JY, Zhou JT, et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 1997, 176:924-932.
11. Reimann KA, Tenner-Racz K, Racz P, Montefiori DC, Yasutomi Y, Lin W, et al. Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Virol 1994, 68:2362-2370.
12. Montefiori DC, Baba TW, Li A, Bilska M, Ruprecht RM. Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239delta3 in adult and infant rhesus monkeys. J Immunol 1996, 157:5528-5535.
13. Ho DD, Sarngadharan MC, Hirsch MS, Schooley RT, Rota TR, Kennedy RC, et al. Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virol 1987, 61:2024-2028.
14. Groopman JE, Benz PM, Ferriani R, Mayer K, Allan JD, Weymouth LA. Characterization of serum neutralization response to the human immunodeficiency virus (HIV). AIDS Res Hum Retroviruses 1987, 3:71-85.
15. Goudsmit J, Ljunggren K, Smit L, Jondal M, Fenyo EM, Jonda M. Biological significance of the antibody response to HIV antigens expressed on the cell surface. Arch Virol 1988, 103:189-206.
16. McKnight A, Clapham PR, Goudsmit J, Cheingsong-Popov R, Weber JN, Weiss RA. Development of HIV-1 group-specific neutralizing antibodies after seroconversion. AIDS 1992, 6: 799-802.
17. Zwart G, Back NK, Ramautarsing C, Valk M, van der Hoek L, Goudsmit J. Frequent and early HIV-1MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from the gp120 V3 domain. AIDS Res Hum Retroviruses 1994, 10:245-251.
18. Meyerhans A, Cheynier R, Albert J, Seth M, Kwok S, Sninsky J, et al. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell 1989, 58:901-910.
19. Kusumi K, Conway B, Cunningham S, Berson A, Evans C, Iversen AK, et al. Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro. J Virol 1992, 66:875-885.
20. Sabino E, Pan LZ, Cheng-Mayer C, Mayer A. Comparison of in vivo plasma and peripheral blood mononuclear cell HIV-1 quasi-species to short-term tissue culture isolates: an analysis of tat and C2-V3 env regions. AIDS 1994, 8:901-909.
21. Spira AI, Ho DD. Effect of different donor cells on human immunodeficiency virus type 1 replication and selection in vitro. J Virol 1995, 69:422-429.
22. Kostrikis LG, Cao Y, Ngai H, Moore JP, Ho DD. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J Virol 1996, 70:445-458.
23. Moore JP, Cao Y, Leu J, Qin L, Korber B, Ho DD. Inter-and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 1996, 70:427-444.
24. Lewis J, Balfe P, Arnold C, Kaye S, Tedder RS, McKeating JA. Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants. J Virol 1998, 72:8943-8951.
25. McKeating JA, Zhang YJ, Arnold C, Frederiksson R, Fenyo EM, Balfe P. Chimeric viruses expressing primary envelope glycoproteins of human immunodeficiency virus type I show increased sensitivity to neutralization by human sera. Virology 1996, 220:450-460.
26. Sonza S, Burgess SH, Crowe SM. Direct quantification of HIV-1 infectivity for monocyte-macrophages using an infectious focus assay. AIDS 1991, 5:571-574.
27. Fuerst TR, Niles EG, Studier FW, Moss B. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci USA 1986, 83:8122-8126.
28. Albert J, Abrahamsson B, Nagy K, Aurelius E, Gaines H, Nystrom G. et al. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 1990, 4:107-112.
29. Lathey JL, Pratt RD, Spector SA. Appearance of autologous neutralizing antibody correlates with reduction in virus load and phenotype switch during primary infection with human immunodeficiency virus type 1. J Infect Dis 1997, 175:231-232.
30. McKeating JA, McKnight A, McIntosh K, Clapham PR, Mulder C, Weiss RA. Evaluation of human and simian immunodeficiency virus plaque and neutralization assays. J Gen Virol 1989, 70(Pt 12):3327-3333.
31. Mackewicz CE, Yang LC, Lifson JD, Levy JA. Non-cytolytic CD8 T-cell anti-HIV responses in primary HIV-1 infection. Lancet 1994, 344:1671-1673.
32. Moore JP, Cao Y, Ho DD, Koup RA. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol 1994, 68: 5142-5155.
33. Moog C, Fleury HJ, Pellegrin I, Kirn A, Aubertin AM. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol 1997, 71:3734-3741.
34. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003, 100:4144-4149.
35. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312.
36. Tremblay M, Wainberg MA. Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. J Infect Dis 1990, 162:735-737.
37. Gloster SE, Newton P, Cornforth D, Lifson DJ, Williams I, Shaw GM, et al. Association of strong virus-specific CD4+ T cell responses with efficient natural control of primary HIV-1 infection. AIDS 2004, in press.
38. Arendrup M, Nielsen CM, Hansen JE, Mathiesen LR, Lindhardt BO, Scheibel E, et al. Neutralizing antibodies against two HIV-1 strains in consecutively collected serum samples: cross neutralization and association to HIV-1 related disease. Scand J Infect Dis 1992, 24:21-28.
39. Burton DR, Saphire EO, Parren PW. A model for neutralization of viruses based on antibody coating of the virion surface. Curr Top Microbiol Immunol 2001, 260:109-143.
40. Spear GT, Sullivan BL, Landay AL, Lint TF. Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis. J Virol 1990, 64:5869-5873.
41. Spear GT, Takefman DM, Sullivan BL, Landay AL, Zolla-Pazner S. Complement activation by human monoclonal antibodies to human immunodeficiency virus. J Virol 1993, 67:53-59.
42. Sullivan BL, Takefman DM, Spear GT. Complement can neutralize HIV-1 plasma virus by a C5-independent mechanism. Virology 1998, 248:173-181.
43. Sereti I, Spear GT. Complement activation by HIV-1-infected target cells enhances IL-2-stimulated but not unstimulated ADCC activity mediated by peripheral blood mononuclear cells. Clin Immunol Immunopathol 1996, 78:77-82.
44. Forthal DN, Landucci G, Keenan B. Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count. AIDS Res Hum Retroviruses 2001, 17:553-561.
45. Forthal DN, Landucci G, Daar ES. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol 2001, 75:6953-6961.
46. Thompson JD, Higgins DC, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucl Acids Res 1994, 22:4673-4680.
47. Rogers JS, Swofford DL. A fast method for approximating maximum likelihoods of phylogenetic trees from nucleotide sequences. Syst Biol 1998, 47:77-89.